腎臓内科診療の掟

出版社： 中外医学社
著者：
発行日： 2023-12-05
分野： 臨床医学：内科  >  腎臓
ISBN： 9784498224902
電子書籍版： 2023-12-05 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

6,380 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,380 円(税込)

購入する

商品紹介

実際の診療を行うにあたって，教科書とレジデント用マニュアルからステップアップするために知っておくべきことを各疾患のエキスパートがわかりやすく解説！
Commonな50の疾患・病態について診療の基本，最新のエビデンス，実際の症例で「掟」がどう役立つか学べる，研修医・若手専門医のための必読書．
診療の柱となる５つの「掟」をおさえておけば日々の臨床に自信が持てる！

目次

  • 1 章 総論：腎疾患の大きな流れをつかむ　　　　
    　 1 身体所見でここまでわかる
    　 2 AKI：尿中バイオマーカーの有用性
    　 3 CKD：標準治療の理解と実践

    2 章 検査：真相にせまる武器
    　 4 尿検査の鉄則
    　 5 尿生化：病態にどこまで迫れるか？
    　 6 画像診断：使い分けとピットフォール
    　 7 腎生検：確定診断の“golden standard”を読み解く

    3 章 水・電解質・酸塩基異常：“能動的”なバランスのとり方
    　 8 溢水（心不全）：多彩な利尿薬の使い方
    　 9 脱水（腎前性腎不全）：高齢者には気をつけよ
    　10 Naの異常：最も難しい生命の“基本”
    　11 Kの異常：救急電解質代表
    　12 Ca，P（CKD-MBD）：電解質の“骨組み”を知る
    　13 Mgの異常：常識を疑え
    　14 酸塩基平衡：病態鑑別のリトマス試験紙

    4 章 糸球体疾患：尿検査異常の原点　　　　
    　15 MCNS：再発と合併症との戦い
    　16 MN：抗体はどこまでわかったか
    　17 FSGS：多彩な糸球体病変に隠されたポドサイト障害
    　18 MPGN（C3腎症）：わかってきた新しい病型分類と概念
    　19 IgA腎症：最も多い腎炎の診断・治療の進歩
    　20 PSAGN：代表的感染性腎炎を見極める 〈藤永周一郎　西野智彦〉　

    5 章 全身疾患：腎臓は体の一部です　
    　21 MPA：予想より多いANCAの意義
    　22 IgA血管炎：小児から成人へ
    　23 抗GBM抗体病：基底膜の破壊とは？
    　24 全身性エリテマトーデス：多様性に富んだ自己免疫疾患の代表
    　25 強皮症：膠原病科のコンサルトに対応する
    　26 IgG4関連疾患（IgG4-RD）：日本で見つかった，新しい概念
    　27 アミロイド：“棘”があります
    　28 骨髄腫腎・MGRS：血液内科からコンサルト，paraprotein腎症とは？
    　29 TMA：分類を整理し，最新の治療に繋げる
    　30 DKD：大きくまとめる，その意義は？
    　31 良性腎硬化症：古くて新しい疾患概念

    6 章 遺伝性疾患：家族歴からルーツをたど　
    　32 ADPKD〔常染色体顕性（優性）多発性嚢胞腎〕：多発する腎嚢胞は，必ずしも嚢胞腎ではない
    　33 Alport症候群：コラーゲンの謎を紐解く
    　34 Fabry病：電顕なしで確定診断をつける
    　35 遺伝子検査：いつ，どのように行うか

    7 章 間質疾患：腎機能障　
    　36 尿細管間質性腎炎：ただの「糸球体じゃない部分」にあらず
    　37 尿細管性アシドーシス：水素と重炭酸の力関係
    　38 悪性腎硬化症：“玉ねぎ”を剥きます

    8 章 特殊な場合の腎障害：一流のコンサルタント　
    　39 悪性腫瘍：原病ですか？　抗がん薬ですか？
    　40 周術期：院内で一目置かれる専門家になる
    　41 造影剤腎症，コレステロール塞栓症候群：転ばぬ先の予防策
    　42 妊娠：一人で二人分を担う母の苦労
    　43 小児：小児と成人の違いによるピットフォールにご用心
    　44 感染症：多彩な変化と，進化する抗菌薬
    　45 COVID-19：世界的な大問題

    9 章 腎代替療法：80年前，腎臓病は100％　
    　46 HD：さらに進化する“標準的”治療法
    　47 PD：遠隔治療も対応できる究極の在宅医療
    　48 Intervention：エコーでできるシャントの管理と治療
    　49 腎移植：増やすためにはどうするの？
    　10 章 社会精神的問題：最後は心の　
    　50 CKM：透析をしないという治療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 総論 : 腎疾患の大きな流れをつかむ

P.9 掲載の参考文献
1) Fawcett RS, Linford S, Stulberg DL. Nail abnormalities:clues to systemic disease. Am Fam Physician. 2004;69:1417-24.
PubMed
2) 東 禹彦. 爪でわかる内科疾患. medicina. 2006;43:1645-7.
 
3) Terry R. White nails in hepatic cirrhosis. Lancet. 1954;266:757-9.
PubMed
4) Nia AM, Ederer S, Dahlem KM, et al. Terry's nails:a window to systemic diseases. Am J Med. 2011;124:602-4.
 
5) Lindsay PG. The half-and-half nail. Arch Intern Med. 1967;119:583-7.
PubMed
6) Muehrcke RC. The finger-nails in chronic hypoalbuminemia. A new physical sign. Br Med J. 1956;1:1327.
 
7) Gross NJ, Hamilton JD. Correlation between the physical signs of hypercapnia and the mixed venous PaO2. Br Med J. 1963;2:1096-7.
 
8) LeBond RF, Brown D, DeGowin R. DeGowin's Diagnostic Examination. 9th ed. New York:McGrawHills;2009. p.473.
 
9) Orient JM, Sapira JD. Sapira's Art & Science of Bedside Diagnosis. 4th ed. Philadelphia:Lippincott Williams & Wilkins;2010. p.436.
 
10) Guarino JR. Auscultatory percussion of the urinary bladder. Arch Intern Med. 1985;145:1823-5.
PubMed
11) 須藤 博. 身体所見から考える水・電解質異常. medicina. 2014;51:240-3.
 
12) Orient JM. In:須藤博他, 監訳. サパイラ 身体診察のアートとサイエンス. 東京:医学書院;2013. p.635.
 
13) 須藤 博. 一目瞭然!目で診る症例. 日内会誌. 2012;101:2367-9.
 
14) Orient JM, Sapira JD. Sapira's Art & Science of Bedside Diagnosis. 4th ed. Philadelphia:Lippincott Williams & Wilkins;2010. p.417-8.
 
15) 須藤 博. "フィジカル・オタク"への道. 総合診療. 2018;28:14-7.
 
P.15 掲載の参考文献
1) Lewington AJ, Cerda J, Mehta RL. Raising awareness of acute kidney injury:a global perspective of a silent killer. Kidney Int. 2013;84:457-67.
PubMed
2) Chen S. Retooling the creatinine clearance equation to estimate kinetic GFR when the plasma creatinine is changing acutely. J Am Soc Nephrol. 2013;24:877-88.
PubMed
3) Doi K, Yuen PS, Eisner C, et al. Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol. 2009;20:1217-21.
PubMed
4) Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on acute kidney injury biomarkers from the Acute Disease Quality Initiative Consensus Conference:a consensus statement. JAMA Netw Open. 2020;3:e2019209.
PubMed
5) Koyner JL, Garg AX, Coca SG, et al. Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol. 2012;23:905-14.
PubMed
6) Klein SJ, Brandtner AK, Lehner GF, et al. Biomarkers for prediction of renal replacement therapy in acute kidney injury:a systematic review and meta-analysis. Intensive Care Med. 2018;44:323-36.
PubMed
7) Koyner JL, Shaw AD, Chawla LS, et al. Tissue Inhibitor Metalloproteinase-2 (TIMP-2)・IGF-Binding Protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI. J Am Soc Nephrol. 2015;26:1747-54.
 
8) Doi K, Nishida O, Shigematsu T, et al. The Japanese Clinical Practice Guideline for acute kidney injury 2016. J Intensive Care. 2018;6:48.
PubMed
9) AKI(急性腎障害)診療ガイドライン2016. 日腎会誌. 2017;59:419-533.
 
10) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. 2012;Suppl 2:1-138.
 
P.25 掲載の参考文献
1) 日本腎臓学会, 編. エビデンスに基づくCKD診療ガイドライン2018. 東京:東京医学社;2018.
 
2) Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
PubMed
3) Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks:cohort study. BMJ. 2017;356:j791.
PubMed
4) Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease:results from the AASK trial. JAMA. 2002;288:2421-31.
PubMed
5) Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):a multicentre, randomized, double-blind, controlled trial. Lancet. 2008;372:547-53.
PubMed
6) Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146-55.
PubMed
7) Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis:a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67:912-24.
 
8) 日本腎臓学会, 編. サルコペニア・フレイルを合併した保存期CKDの食事療法の提言. 日腎会誌. 2019;61:525-56.
 
9) Yamagata K, Makino H, Iseki K, et al. Effect of behavior modification on outcome in early- to moderate-stage chronic kidney disease:a cluster-randomized trial. PLoS One. 2016;11:e0151422.
PubMed
10) Imasawa T, Saito C, Kai H, et al. Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management:an extended follow-up of cluster-randomized FROM-J study. Nephrol Dial Transplant. 2023;38:158-66.
 
11) Ueki K, Sasako T, Okazaki Y, et al. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int. 2021;99:256-66.
 
12) Chan JC, So WY, Yeung CY, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes:the SURE study:a randomized multicenter translational study. Diabetes Care. 2009;32:977-82.
PubMed
13) Imamura Y, Takahashi Y, Hayashi T, et al. Usefulness of multidisciplinary care to prevent worsening renal function in chronic kidney disease. Clin Exp Nephrol. 2019;23:484-92.
PubMed
14) AMED長寿科学研究開発事業「高齢腎不全患者に対する腎代替療法の開始/見合わせの意思決定プロセスと最適な緩和医療・ケアの構築」研究班. 高齢腎不全患者のための保存的腎臓療法-Conservative kidney management(CKM)の考え方と実践-. 東京:東京医学社;2022.
 
15) Inoue R, Nishi H, Tanaka T, et al. Regional variance in patterns of prescriptions for chronic kidney disease in Japan. Clin Exp Nephrol. 2019;23:859-64.
PubMed
16) 日本腎臓学会, 日本医学放射線学会, 日本循環器学会, 編. 腎障害患者におけるヨード造影剤使用に関するガイドライン2018. 東京:東京医学社;2018.
 

2章 検査 : 真相にせまる武器

P.31 掲載の参考文献
1) Cavanaugh C, Perazella MA. Urine sediment examination in the diagnosis and management of kidney disease:Core Curriculum 2019. Am J Kidney Dis. 2019;73:258-72.
PubMed
2) Perazella MA, Coca SG, Hall IE, et al. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol. 2010;5:402-8.
PubMed
3) Imai E, Horio M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population:a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433-41.
PubMed
P.39 掲載の参考文献
1) Kamel KS, Halperin ML. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium:an hypothesis with clinical implications. Curr Opin Nephrol Hypertens. 2011;20:547-64.
PubMed
2) Winter SD. Measurement of urine electrolytes:clinical significance and methods. Crit Rev Clin La Sci. 1981;14:163-87.
 
3) Abdelhafez M, Nayfeh T, Atieh A, et al. Diagnostic performance of fractional excretion of sodium for the differential diagnosis of acute kidney injury:A systemic review and meta-analysis. Clin J Am Soc Nephrol. 2022;17:785-97.
 
P.45 掲載の参考文献
1) Catalano O, Nunziata A, Altei F, et al. Suspected ureteral colic:primary helical CT versus selective helical CT after unenhanced radiography and sonography. AJR Am J Roentgenol. 2002;178:379-87.
PubMed
2) Ichioka K, Saito R, Matsui Y, et al. Diffusion-weighted magnetic resonance imaging of infected renal cysts in a patient with polycystic kidney disease. Urology. 2007;70:1219.
 
3) Kita Y, Soda T, Terai A. Diagnosis and localization of infected renal cyst by diffusion-weighted magnetic resonance imaging in polycystic kidney disease. Int J Urology. 2009;16:918-9.
 
4) 日本腎臓学会, 編. エビデンスに基づくCKD診療ガイドライン2018. 東京:東京医学社;2018.
 
5) Spatola L, Andrulli S. Doppler ultrasound in kidney diseases:a key parameter in clinical long-term follow-up. J Ultrasound. 2016;19:243-50.
 
6) Bellos I, Pergialiotis V, Kontzoglou K. Renal resistive index as predictor of acute kidney injury after major surgery:a systematic review and meta-analysis. J Crit Care. 2019;50:36-43.
PubMed
7) Parolini C, Noce A, Staffolani E, et al. Renal resistive index and long-term outcome in chronic nephropathies. Radiology. 2009;252:888-96.
PubMed
8) Sugiura T, Nakamori A, Wada A, et al. Evaluation of tubulointerstitial injury by Doppler ultrasonography in glomerular diseases. Clin Nephrol. 2004;61:119-26.
PubMed
9) 日本消化器がん検診学会. 腹部超音波検診判定マニュアル改訂版(2021年). 日本消化器がん検診学会雑誌. 2022;60:123-81.
 
10) Miletic D, Fuckar Z, Sustic A, et al. Sonographic measurement of absolute and relative renal length in adults. J Clin Ultrasound. 1998;26:185-9.
PubMed
11) O'Neill WC. Sonographic evaluation of renal failure. Am J Kidney Dis. 2000;35:1021-38.
PubMed
12) 山口 聡, 藤井 敬, 金子茂男, 他. 急性腎性腎不全の腎超音波像の検討. 日本泌尿器科学会雑誌. 1991;82:1561-7.
 
13) 日本腎臓学会, 編. エビデンスに基づくCKD診療ガイドライン2009. 東京:東京医学社;2009.
 
14) Platt JF, Rubin JM, Bowerman RA, et al. The inability to detect kidney disease on the basis of echogenicity. Am J Roentgenol. 1988;151:317-9.
 
15) Wiersma F, Toorenvliet BR, Ruige M, et al. Increased echogenicity of renal cortex:a transient feature in acutely ill children. Am J Roentgenol. 2008;190:240-3.
 
16) Sevcenco S, Spick C, Helbich TH, et al. Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography-a systematic review and meta-analysis. Eur Radiol. 2017;27:2239-47.
PubMed
17) 貴田岡 正, 秋山 隆, 沖原 宏, 他. 腎細胞癌と他の腎腫瘤性病変の鑑別(案). 超音波医学. 2012;39:485-9.
 
18) Doi Y, Iwashima Y, Yoshihara F, et al. Renal resistive index and cardiovascular and renal outcomes in essential hypertension. Hypertension. 2012;60:770-7.
PubMed
19) Viazzi F, Leoncini G, Derchi LE, et al. Ultrasound Doppler renal resistive index:a useful tool for the management of the hypertensive patient. J Hypertens. 2014;32:149-53.
 
P.53 掲載の参考文献
1) 腎生検ガイドブック-より安全な腎生検を施行するために. 日本腎臓学会腎生検検討委員会, 編. 東京:東京医学社;2004.
 
2) 日本腎臓学会, 腎生検ガイドブック改定委員会, 編. 腎生検ガイドブック2020. 東京:東京医学社;2020.
 
3) 日本腎病理協会, 日本腎臓学会 腎病理標準化委員会, 編. 腎生検病理診断取扱い規約, General rule for renal biopsy diagnosis. 東京:東京医学社;2019.
 
4) 日本腎病理協会, 日本腎臓学会, 編. 腎生検病理アトラス 改訂版, Kidney biopsy-Atlas and text. 東京:東京医学社;2017.
 
5) 大橋健一, 小池淳樹, 冨田茂樹, 他編. 非腫瘍性疾患病理アトラス 腎, Non-neoplastic disease pathology atlas-Kidney. 東京:文光堂;2022.
 

3章 水・電解質・酸塩基異常 : "能動的" なバランスのとり方

P.62 掲載の参考文献
1) Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377:1964-75.
PubMed
2) Matsue Y, Damman K, Voors AA, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042-51.
PubMed
3) Chioncel O, Mebazaa A, Harjola VP, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure:the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1242-54.
 
4) Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion-a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137-55.
 
5) Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252:572-4.
PubMed
6) Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial. JAMA. 2007;297:1319-31.
PubMed
7) 日本循環器学会/日本心不全学会・合同研究班. 急性・慢性心不全診療ガイドライン(JCS 2017/JHS 2017).
 
8) 日本循環器学会/日本心不全学会・合同研究班. 2021年JCS/JHS 2021ガイドラインフォーカスアップデート版 急性・慢性心不全診療.
 
9) Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27.
PubMed
10) Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46.
PubMed
11) McMurray JJ, Packer M, Desai AS, et al;PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
PubMed
12) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726.
PubMed
13) Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.
 
14) Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment;results from the K-STAR Study. Circ J. 2017;82:159-67.
 
15) Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185-95.
PubMed
16) Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure:diuretic and cardiorenal effects. Circulation. 2020;142:1028-39.
PubMed
17) Banerjee D, Rosano G, Herzog CA. Management of heart failure patient with CKD. Clin J Am Soc Nephrol. 2021;16:1131-9.
PubMed
18) Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure:the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329:214.
PubMed
P.68 掲載の参考文献
1) 守山敏樹. 高齢者におけるAKIの特徴と治療. 透析会誌. 2018;51:175-9.
 
2) 平田純生, 門脇大介, 成田勇樹. 薬剤性腎前性急性腎障害～薬剤性腎性急性腎障害との鑑別と原因薬物について～. 日本腎臓薬物療法学会誌. 2013;2(3):3-12.
 
3) Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20:223-8.
PubMed
4) Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a lowsalt diet. A randomized, controlled trial. Ann Intern Med. 2000;133:1-9.
 
5) Sun WY, Reiser IW, Chou SY. Risk factors for acute renal insufficiency induced by diuretics in patients with congestive heart failure. Am J Kidney Dis. 2006;47:798-808.
PubMed
6) Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66:1115-22.
PubMed
P.75 掲載の参考文献
1) Upadhyay A, Jaber BL, Madias NE. Epidemiology of hyponatremia. Semin Nephrol. 2009;29:227-38.
PubMed
2) Hiller TA, Abbott RD, Barrett EJ. Hyponatremia:evaluating the correction factor for hyperglycemia. Am J Med. 1999;106:399-403.
 
3) Turchin A, Seifter JL, Seely EL. Clinical problem-solving. Mind the gap. N Engl J Med. 2003;349:1465-9.
 
4) Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatremia. Nephrol Dial Transplant. 2014;29 Suppl 2:i1-i39.
 
5) McGee S, Abernethy WB 3rd, Simel DL. The rational clinical examination. Is this patient hypovolemic? JAMA. 1999;281:1022-9.
PubMed
6) Vinayak AG, Levitt J, Gehlbach B, et al. Usefulness of the external juglar vein in detecting abnormal central venous pressure in critically ill patients. Arch Intern Med. 2006;166:2132-7.
 
7) McGee SR. Evidence based physical diagnosis. 2nd ed. USA:WB Saunders;2006. Chapter 15, 32, 44, 45.
 
8) Adrogue HJ. Madias NE. Hypernatremia. N Engl J Med. 2000;342:1493-9.
PubMed
9) Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia:expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-42.
 
10) Vilapurathu JK, Rajarajan S. A prospective study to compare the clinical efficacy of Tolvaptan with 3% hypertonic saline solution in hospitalized patients having hyponatremia. J Res Pract. 2014;3:34-6.
 
11) Refardt J, Imber C, Nobbenhuis R, et al. Treatment effect of the SGLT2 Inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis:results of a randomized, double-blind, placebo-controlled, crossover trial. J Am Soc Nephrol. 2023;34:322-32.
PubMed
P.88 掲載の参考文献
1) Clase CM, Carrero JJ, David H, et al. Potassium homeostasis and management of dyskalemia in kidney diseases:conclusions from a Kidney Disease:Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97:42-61.
 
2) Acker CG, Johnson JP, Palevsky PM, et al. Hyperkalemia in hospitalized patients:causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158:917-24.
PubMed
3) Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis:core curriculum 2019. Am J Kidney Dis. 2019;74:682-95.
PubMed
4) Blumberg A, Roser HW, Zehnder C, et al. Plasma potassium in patients with terminal renal failure during and after haemodialysis;relationship with dialytic potassium removal and total body potassium. Nephrol Dial Transplant. 1997;12:1629-34.
PubMed
5) Squires RD, Huth EJ. Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. J Clin Invest. 1959;38:1134-48.
 
6) Yu A, Chertow G, Valerie Luyckx V, et al. Brenner and Rector's The Kidney, 2-Volume Set. 11th ed. Chap.17. Elsevier;2019.
 
7) Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004:21;43:155-61.
 
8) Wu KL, Cheng CJ, Sung CC, et al. Identification of the causes for chronic hypokalemia:importance of urinary sodium and chloride excretion. Am J Med. 2017;130:846-55.
PubMed
9) 深川雅史, 監修. 柴垣有吾. より理解を深める!体液電解質異常と輸液. 改訂3版. 東京:中外医学社;2007.
 
10) 小松康宏. 腎臓病診療に自信がつく本 第2版. 埼玉:カイ書林;2016.
 
P.95 掲載の参考文献
1) Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-8.
PubMed
2) Komaba H, Fukagawa M. FGF23-parathyroid interaction:implications in chronic kidney disease. Kidney Int. 2010;77:292-8.
PubMed
3) Sakaguchi Y, Fujii N, Shoji T, et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85:174-81.
PubMed
4) Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520-8.
PubMed
5) Kovesdy CP, Kuchmak O, Lu JL, et al. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis. 2010;56:842-51.
PubMed
6) Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432-9.
 
7) Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407-15.
PubMed
8) 日本腎臓学会, 編. エビデンスに基づくCKD診療ガイドライン2018. 日腎会誌. 2018;60:1037-193.
 
9) Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease:the PRIMO randomized controlled trial. JAMA. 2012;307:674-84.
PubMed
10) Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD-the OPERA trial. J Am Soc Nephrol. 2014;25:175-86.
 
11) Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update:what's changed and why it matters. Kidney Int. 2017;92:26-36.
PubMed
12) Matsui I, Oka T, Kusunoki Y, et al. Cardiac hypertrophy elevates serum levels of fibroblast growth factor23. Kidney Int. 2018;94:60-71.
 
P.101 掲載の参考文献
1) Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18:2649-52.
PubMed
2) Bibawy JN, Parikh V, Wahba J, et al. Pantoprazole (proton pump inhibitor) contributing to Torsades de Pointes storm. Circ Arrhythm Electrophysiol. 2013;6:e17-9.
PubMed
3) Willox JC, McAllister EJ, Sangster G, et al. Effects of magnesium supplementation in testicular cancer patients receiving cisplatin:a randomised trial. Br J Cancer. 1986;54:19-23.
 
4) Hsieh MC, Wu CF, Chen CW, et al. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer:a systematic review and meta-analysis. Sci Rep. 2018;8:2047.
PubMed
5) Oka T, Hamano T, Sakaguchi Y, et al. Proteinuria-associated renal magnesium wasting leads to hypomagnesemia:a common electrolyte abnormality in chronic kidney disease. Nephrol Dial Transplant. 2019;34:1154-62.
PubMed
6) Shimizu T, Takayanagi K, Iwashita T, et al. Down-regulation of magnesium transporting molecule, claudin-16, as a possible cause of hypermagnesiuria with the development of tubulo-interstitial nephropathy. Magnes Res. 2018;31:11-23.
PubMed
7) Kondo A, Nagano C, Ishiko S, et al. Examination of the predicted prevalence of Gitelman syndrome by ethnicity based on genome databases. Sci Rep. 2021;11:16099.
PubMed
8) Joshi S, McMacken M, Kalantar-Zadeh K. Plant-based diets for kidney disease:a guide for clinicians. Am J Kidney Dis. 2021;77:287-96.
PubMed
9) 国民健康・栄養調査. 栄養素等摂取量. 国立健康・栄養研究所. https://www.nibiohn.go.jp/eiken/kenkounippon21/eiyouchousa/koumoku_eiyou_chousa.html
 
10) 金澤良枝, 城田直子, 中尾俊之. 透析患者における食事マグネシウム補給について. 透析会誌. 2020;53:147-51.
 
11) Sakaguchi Y. The emerging role of magnesium in CKD. Clin Exp Nephrol. 2022;26:379-84.
PubMed
12) Sakaguchi Y, Fujii N, Shoji T, et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85:174-81.
PubMed
P.107 掲載の参考文献
1) 今井裕一. 酸塩基平衡, 水・電解質が好きになる. 東京:羊土社;2007.
 
2) 今井裕一, 笠置智道. 血液ガス分析のプロフェッショナルになるにはどうすればよいですか? In:和田隆志, 坂井宣彦, 編. 腎臓内科Controversy. 東京:中外医学社;2021. p.105-11.
 
3) Achanti A, Szerlip HM. Acid-base disorders in the critically ill patient. Clin J Am Soc Nephrol. 2023;18:102-12.
PubMed
4) Mehta AN, Emmett JB, Emmett M. GOLD MARK:an anion gap mnemonic for the 21st Century. Lancet. 2008;372:892.
 
5) Liamis G, Filippatos TD, Liontos A, et al. Serum osmolal gap in clinical practice:usefulness and limitations. Postgrad Med. 2017;129:456-9.
PubMed

4章 糸球体疾患 : 尿検査異常の原点

P.113 掲載の参考文献
1) 成田一衛, 監修. エビデンスに基づくネフローゼ症候群診療ガイドライン2020. 東京:東京医学社;2020.
 
2) Kidney Disease:Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1-276.
PubMed
3) Vivarelli M, Massella L, Ruggiero B, et al. Minimal change disease. Clin J Am Soc Nephrol. 2017;12:332-45.
PubMed
4) Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7:513-20.
PubMed
5) Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease:clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445-53.
PubMed
6) Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850-63.
PubMed
7) Iwabuchi Y, Takei T, Moriyama T, et al. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine. 2014;93:e300.
PubMed
8) Takei T, Itabashi M, Moriyama T, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013;28:1225-32.
PubMed
9) 日本結核病学会予防委員会・治療委員会. 潜在性結核感染症治療指針. Kekkaku. 2013;88:497-512.
Medical*Online
10) 日本結核病学会予防委員会・治療委員会. 潜在性結核感染症治療レジメンの見直し. Kekkaku. 2019;94:515-8.
Medical*Online
11) 骨粗鬆症の予防と治療ガイドライン作成委員会, 編. 骨粗鬆症の予防と治療ガイドライン2015年版. 東京:ライフサイエンス出版;2015.
 
12) ステロイド性骨粗鬆症の管理と治療ガイドライン改訂委員会, 編. ステロイド性骨粗鬆症の管理と治療ガイドライン:2014年改訂版. J Bone Miner Metab. 2014;32:337-50.
 
13) 資料3 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン. In:日本肝臓学会, 編. B型肝炎治療ガイドライン(第4版). 2022年6月.
 
14) Watts AJB, Keller KH, Lerner G, et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol. 2022;33:238-52.
PubMed
P.120 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)「難治性腎障害に関する調査研究」班, 編.エビデンスに基づくネフローゼ症候群診療ガイドライン. 東京医学社;2020.
 
2) Yamamoto R, Imai E, Maruyama S, et al. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome:the Japan nephrotic syndrome cohort study. Clin Exp Nephrol. 2018;22:1266-80.
PubMed
3) Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400-7.
PubMed
4) Yokoyama H, Taguchi T, Sugiyama H, et al. Membranous nephropathy in Japan:analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:557-63.
PubMed
5) Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11-21.
PubMed
6) Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371:2277-87.
PubMed
7) Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97:163-74.
PubMed
8) Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/Exostosin 2-associated membranous nephropathy. J Am Soc Nephrol. 2019;30:1123-36.
PubMed
9) Alsharhan L, Beck LH Jr. Membranous nephropathy:core curriculum 2021. Am J Kidney Dis. 2021;77:440-53.
PubMed
10) Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy:a meta-analysis. PLoS One. 2014;9:e104936.
 
11) Kidney Disease:Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
PubMed
12) Akiyama S, Akiyama M, Imai E, et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol. 2015;19:653-60.
 
13) Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12:983-97.
PubMed
14) Larsen CP, Messias NC, Silva FG, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2013;26:709-15.
PubMed
15) Ponticelli C, Glassock RJ. Glomerular diseases:membranous nephropathy-a modern view. Clin J Am Soc Nephrol. 2014;9:609-16.
PubMed
16) Nuffield Department of Population Health Renal Studies Group;SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes:collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788-801.
 
17) Niihata K, Nishiwaki H, Kurita N, et al. Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan:certified nephrologists' questionnaire survey. Clin Exp Nephrol. 2019;23:1288-97.
PubMed
18) Yamamoto R, Imai E, Maruyama S, et al. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome:the Japan Nephrotic Syndrome Cohort Study (JNSCS). Clin Exp Nephrol. 2020;24:526-40.
PubMed
19) Yamaguchi M, Ando M, Yamamoto R, et al. Patient age and the prognosis of idiopathic membranous nephropathy. PLoS One. 2014;9:e110376.
PubMed
20) Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36-46.
 
21) Hoxha E, Harendza S, Pinnschmidt H, et al. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One. 2014;9:e110681.
PubMed
22) De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421-30.
PubMed
P.128 掲載の参考文献
1) 成田一衛, 監修. エビデンスに基づくネフローゼ症候群ガイドライン2020. 東京:東京医学社;2020. p.9-10, 21-6, 30-3, 50-1.
 
2) D'Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis:a working proposal. Am J Kidney Dis. 2004;43:368-82.
PubMed
3) 日本腎病理協会, 日本腎臓学会腎病理標準化委員会, 編. 腎生検病理診断取扱い規約. 東京:金原出版;2019. p.156.
 
4) Thomas DB, Franceschini N, Hogan SL. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 2006;69:920-6.
PubMed
5) Deegens JKJ, Dijkman HBPM, Borm GF, et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int. 2008;74:1568-76.
PubMed
6) Vriese ASD, Sethi S, Nath KA, et al. Differentiating primary, genetic, and secondary FSGS in adults:a clinicopathologic approach. J Am Soc Nephrol. 2018;29:759-74.
 
7) 長田道夫. 巣状分節性糸球体硬化症. In:日本腎病理協会, 他編. 腎生検病理アトラス 改訂版. 東京:東京医学社;2017. p.97-104.
 
8) 城 謙輔. 電顕像のartifactとその対処法. ジョーシキ! 腎生検電顕ATLAS. 東京:南山堂;2016. p.210-4.
 
P.133 掲載の参考文献
1) Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol. 2010;25:1409-18.
PubMed
2) 金子佳賢. 膜性増殖性糸球体腎炎I型, III型. 腎炎症候群(第3版)I-その他の腎疾患を含めて-. 別冊日本臨牀. 2022;22:122-6.
 
3) 辻 隆裕, 深澤雄一郎. 膜性増殖性糸球体腎炎. In:本田一穂, 他編. 腎生検病理アトラス 改訂版. 2版. 東京:東京医学社;2020. p.132-8.
 
4) 成田一衛, 監修. エビデンスに基づくネフローゼ症候群診療ガイドライン2020. 東京:東京医学社;2020. p.10-2.
 
5) Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol. 2015;11:14-22.
PubMed
6) Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis:clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012;82:465-73.
PubMed
7) Servais A, Noel LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play acritical role in dense deposit desease and other C3 glomerulopathies. Kidney Int. 2012;82 454-64.
 
8) West CD, McAdams AJ, McConville JM, et al. Hypocomplementemic and normocomplementemic persistent (Chronic) glomerulonephritis;clinical and pathological characteristics. J Pediatr. 1965;67:1089-112.
 
9) Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med. 1983;74:175-92.
 
10) Rennke HG. Secondary membranoproliferative glomerulonephritis. Kidney Int. 1995;47:643-56.
PubMed
11) 金子佳賢, 成田一衛. 膜性増殖性糸球体腎炎. In:下条文武, 監修. 専門医のための腎臓病学. 2版. 東京:医学書院;2009. p.344-50.
 
12) Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy:conclusions from a "Kidney Disease:Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91:539-51.
PubMed
13) Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-seposit disease. N Engl J Med. 2012;366:1161-3.
 
14) Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-seposit disease. N Engl J Med. 2012;366:1163-5.
PubMed
15) Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7:748-56.
PubMed
16) Nakagawa N, Mizuno M, Kato S, et al. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan:A retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One. 2021;16:e0257397.
PubMed
P.140 掲載の参考文献
1) 成田一衛, 監修. エビデンスに基づくIgA腎症診療ガイドライン2020. 東京:東京医学社;2020. p.32-3.
 
2) Matsuzaki K, Aoki R, Nihei Y, et al. Gross hematuria after SARS-CoV-2 vaccination:questionnaire survey in Japan. Clin Exp Nephrol. 2022;26:316-22.
PubMed
3) Gesualdo L, Leo VD, Coppo R. The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021;43:657-68.
 
4) Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin a nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29:526-32.
 
5) 花房規男, 阿部雅紀, 常喜信彦, 他. わが国の慢性透析療法の現況(2020年12月31日現在). 透析会誌. 2021;54:611-57.
 
6) Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2019;23:26-31.
PubMed
7) Yasutake J, Suzuki Y, Suzuki H, et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015;30:1315-21.
PubMed
8) Saha MK, Julian BA, Novak A, et al. Secondary IgA nephropathy. Kidney Int. 2018;94:674-81.
 
9) Lee M, Suzuki H, Kato R, et al. Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy. CEN Case Rep. 2021;10:17-22.
 
10) 川村哲也, 城 謙輔, 宇都宮保典, 他. IgA腎症診療指針第3版:厚生労働科学研究費補助金 難治性疾患克服研究事業 進行性腎障害に関する調査研究班報告 IgA腎症分科会. 日腎会誌. 2011;53:123-35.
 
11) Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy:rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534-45.
PubMed
12) Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016:an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91:1014-21.
 
13) Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179:942-52.
PubMed
14) Huang X, Xu G. An update on targeted treatment of IgA nephropathy:an autoimmune perspective. Front Pharmacol. 2021;12:715253.
PubMed
15) Duan J, Liu D, Duan G, et al. Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy:a meta-analysis. Int Urol Nephrol. 2017;49:103-12.
PubMed
16) Hirano K, Matsuzaki K, Yasuda T, et al. Association between tonsillectomy and outcomes in patients with immunoglobulin a nephropathy. JAMA Netw Open. 2019;2:e194772.
PubMed
17) Tomino Y, Suzuki S, Imai H, et al. Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. J Clin Lab Anal. 2000;14:220-3.
PubMed
18) Maeda A, Gohda T, Funabiki K, et al. Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal. 2003;17:73-6.
PubMed
P.147 掲載の参考文献
1) Rodriguez-Iturbe B, Najafian B, Silva A, et al. Acute Postinfectious Glomerulonephritis in Children. In:Avner ED, et al. Editors. Pediatric Nephrology. 7th ed. Berlin:Springer;2016. p.959-81.
 
2) Niaudet P, et al. Poststreptococcal glomerulonephritis. UpToDate last updated May 20, 2020.
 
3) Eison TM, Ault BH, Jones DP, et al. Post-streptococcal acute glomerulonephritis in children:clinical features and pathogenesis. Pediatr Nephrol. 2011;26:165-80.
PubMed
4) 大友義之. 急性感染後急性糸球体腎炎. In:日本小児腎臓病学会, 編. 小児腎臓病学 改訂第2版. 東京:診断と治療社;2017. p.226-9.
 
5) 鈴木重伸, 竹村 司. 急性糸球体腎炎. In:内山 聖, 他編. 専門医のための腎臓病学 第2版. 東京:医学書院;2009. p.263-74.
 
6) 日本高血圧学会高血圧治療ガイドライン作成委員会, 編.高血圧治療ガイドライン2019. 東京:ライフサイエンス出版;2019.
 
7) Fujinaga S, Ohtomo Y, Umino D, et al. Pulmonary edema in a boy with biopsy-proven poststreptococcal glomerulonephritis without urinary abnormalities. Pediatr Nephrol. 2007;22:154-5.
 
8) 伊藤 研, 相良長俊, 日馬由貴, 他. 心不全を契機に診断された腎外症候性急性糸球体腎炎の1例. 小児科臨床. 2017;70:558-62.
Medical*Online
9) 真島久和, 藤田直也, 山川 聡, 他. けいれんを契機に診断にいたった腎外症候性腎炎の1例. 小児内科. 2017;49:302-6.
Medical*Online
10) 西崎直人, 平野大志, 金井宏明, 他. 様々な臨床経過を呈した腎外症候性腎炎を含む急性糸球体腎炎の4例. 小児高血圧研究会誌. 2010;7:36-43.
 
11) 水川花織, 小林貴子, 山田伸治, 他. 細菌性肺炎に急性腎障害を伴い, 後日溶連菌感染後急性糸球体腎炎と診断した1例. 小児科臨床. 2013;66:2251-5.
 
12) 加地更紗, 成相昭吉, 堀江昭好. 補体C3低値を背景に非PCV13血清型による侵襲性肺炎球菌感染症を発症した2小児例. 小児科臨床. 2022;75:23-7.
Medical*Online
13) 藤永周一郎. 急性腎炎, 急性腎不全. In:金子一成, 編. すぐに使える小児輸液ハンドブック. 東京:中外医学社;2012. p.130-7.
 
14) 西野智彦, 藤永周一郎. 溶連菌感染後急性糸球体腎炎. 小児科. 2018;59:1535-40.
 
15) Hoy WE, White AV, Dowling A, et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int. 2012;81:1026-32.
 
16) Vivante A, Twig G, Tirosh A, et al. Childhood history of resolved glomerular disease and risk of hypertension during adulthood. JAMA. 2014;311:1155-7.
PubMed
17) Calderon-Margalit R, Golan E, Twig G, et al. History of childhood kidney disease and risk of adult end-stage renal disease. N Engl J Med. 2018;378:428-38.
PubMed

5章 全身疾患 : 腎臓は体の一部です

P.153 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1-11.
 
2) Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222-7.
PubMed
3) Sada KE, Yamamura M, Harigai M, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16:R101.
 
4) Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628-36.
PubMed
5) Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94:1177-88.
PubMed
6) 川嶋聡子, 要 伸也. 【症例で学ぶ!腎泌尿器診療ガイドラインの使い方】(第9章)自己免疫疾患 ANCA関連血管炎. 腎と透析. 2020;88巻増刊:398-404.
 
7) 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業), 編. ANCA関連血管炎診療ガイドライン2017. 東京:診断と治療社;2017. p.58-60.
 
8) 成田一衛, 監修. エビデンスに基づく急速進行性腎炎症候群(RPGN)診療ガイドライン2020. 東京:東京医学社;2020.
 
9) Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622-31.
PubMed
10) Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis:A Randomized Clinical Trial. JAMA. 2021;325:2178-87.
PubMed
11) Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017;28:2756-67.
PubMed
P.160 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitis. Arthritis Rheum. 2013;65;1-11.
 
2) Jeusic M, Sestan M. IgA vasculitis or Henoch-Schonlein purpura:genetics and beyond. Pediatr Nephrol. 2021;36:2149-23.
PubMed
3) Peruzzi L, Coppo R. IgA vasculitis nephritis in children and adults:one or different entities? Pediatr Nephrol. 2021;36:2615-25.
 
4) Kidney Disease:Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1-S276.
PubMed
5) Counahan R, Winterborn MH, White RH, et al. Prognosis of Henoch-Schonlein nephritis in children. Br Med J. 1977;2:11-4.
PubMed
6) Fukui H, Kamitsuji H, Nagao T, et al. Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schonlein purpura. Japanese Pediatric Group. Thromb Res. 1989;56:667-75.
 
7) 金子一成, 清水正樹, 野津寛大, 他. In:日本小児腎臓病学会, 編. 小児IgA血管炎診療ガイドライン2023. 東京:診断と治療社;2023:p.44-9.
 
8) 成田一衛, 監修.厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班, 編. エビデンスに基づくIgA腎症診療ガイドライン2020. 東京:東京医学社;2020.
 
9) Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, et al. Henoch-Schonlein purpura in adulthood and childhood:two different expressions of the same syndrome. Arthritis Rheum. 1997;40:859.
PubMed
10) Pillebout E, Thervet E, Hill G, et al. Henoch-Schonlein purpura in adults:outcome and prognostic factors, J Am Soc Nephrol. 2002;13:1271-8.
PubMed
P.165 掲載の参考文献
1) 成田一衛, 監修. エビデンスに基づく急速進行性腎炎症候群(RPGN)診療ガイドライン2020. 東京:東京医学社;2020.
 
2) 指定難病診断基準 抗糸球体基底膜腎炎(指定難病221). https://www.nanbyou.or.jp/entry/4379
 
3) Segelmark M, Hellmark T. Anti-glomerular basement membrane disease:an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant. 2019;34:1826-32.
PubMed
4) McAdoo SP, Tanna A, Hruskova Z, et al. Patients double-seropositive for ANCA and antiGBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693-702.
PubMed
5) McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12:1162-72.
PubMed
P.172 掲載の参考文献
1) 加藤保宏. 高齢発症SLEの特徴と治療. 臨床リウマチ. 2018;30:23-7.
 
2) Frutos AR, Holgado S, Sanvisens A, et al. Late-onset versus early-onset systemic lupus:characteristics and outcome in a national multicentre register (RELESSER). Rheumatology. 2021;60:1793-803.
 
3) Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for systemic lupus erythematosus. Arthritis Rheum. 2019;71:1400-12.
 
4) Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
PubMed
5) 厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究(自己免疫班), 日本リウマチ学会, 編. 全身性エリテマトーデス診療ガイドライン2019. 東京:南山堂;2019.
 
6) Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-28.
 
7) van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus:recommendations from an international task force. Ann Rheum Dis. 2014;73:958-67.
PubMed
8) Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus. 2006;15:94-101.
PubMed
9) Siso A, Ramos-Casals M, Bove A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis:influence on outcomes and survival. Lupus. 2008;17:281-8.
PubMed
10) Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus:a systematic review. Ann Rheum Dis. 2010;69:20-8.
PubMed
11) Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology. Nat Rev Rheumatol. 2020;16:155-66.
PubMed
12) Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453-60.
PubMed
13) Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117-28.
PubMed
P.181 掲載の参考文献
1) Steen VD, Syzd A, Johnson JP, et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol. 2005;32:649-55.
PubMed
2) Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis:a report from the EULAR Scleroderma Trials And Research Group Database. Ann Rheum Dis. 2007;66:754-63.
 
3) Hashimoto A, Endo H, Kondo H, et al. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol. 2012;22:272-9.
PubMed
4) Trostle DC, Bedetti CD, Steen VD, et al. Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum. 1988;31:393-400.
PubMed
5) Moxey J, Huq M, Proudman S, et al. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. Arthritis Res Ther. 2019;21:57.
PubMed
6) Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S29-31.
 
7) Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis:a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67:110-6.
PubMed
8) Panopoulos ST, Bournia VK, Sfikakis PP. Is vasculopathy associated with systemic sclerosis more severe in men? J Rheumatol. 2013;40:46-51.
 
9) Helfrich DJ, Banner B, Steen VD, et al. Normotensive renal failure in systemic sclerosis. Arthritis Rheum. 1989;32:1128-34.
PubMed
10) Hudson M, Baron M, Tatibouet S, et al;International Scleroderma Renal Crisis Study I. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43:666-72.
 
11) Manadan AM, Harris C, Block JA. Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum. 2005;34:683-8.
PubMed
12) Walker KM, Pope J. Treatment of systemic sclerosis complications:what to use when first-line treatment fails--a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42-55.
 
13) Hudson M, Baron M, Tatibouet S, et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43:666-72.
 
14) Zanatta E, Codullo V, Allanore Y. Scleroderma renal crisis:case reports and update on critical issues. Eur J Rheumatol. 2021;8:162-7.
PubMed
15) Yamashita H, Kamei R, Kaneko H. Classifications of scleroderma renal crisis and reconsideration of its pathophysiology. Rheumatology (Oxford). 2019;58:2099-106.
PubMed
16) Cozzi F, Marson P, Cardarelli S, et al. Prognosis of scleroderma renal crisis:a long-term observational study. Nephrol Dial Transplant. 2012;27:4398-403.
PubMed
17) Takada D, Hoshino J, Kikuchi K, et al. Anti-RNA polymerase III antibody-associated scleroderma renal crisis in a patient with limited cutaneous systemic sclerosis:a case report. Mod Rheumatol. 2018;28:369-72.
 
P.188 掲載の参考文献
1) Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366:539-51.
PubMed
2) Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78:1016-23.
PubMed
3) Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732-8.
PubMed
4) Hamano H, Kawa S, Ochi Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet. 2002;359:1403-4.
 
5) Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38:982-4.
 
6) Yamada K, Yamamoto M, Saeki T, et al. New clues to the nature of immunoglobulin G4-related disease:a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther. 2017;19:262.
 
7) Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67:1688-99.
PubMed
8) Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol. 2021;31:529-33.
PubMed
9) Hara S, Kawano M, Mizushima I, et al. Distribution and components of interstitial inflammation and fibrosis in IgG4-related kidney disease:analysis of autopsy specimens. Hum Pathol. 2016;55:164-73.
PubMed
10) Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League against rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79:77-87.
PubMed
11) Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League against rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol. 2020;72:7-19.
PubMed
12) Saeki T, Nagasawa T, Ubara Y, et al. Validation of the 2019 ACR/EULAR criteria for IgG4-related disease in a Japanese kidney disease cohort:a multicentre retrospective study by the IgG4-related kidney disease working group of the Japanese Society of Nephrology. Ann Rheum Dis. 2021;80:956-7.
 
13) Kawano M, Saeki T, Nakashima H, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol. 2011;15:615-26.
PubMed
14) Saeki T, Kawano M, Nagasawa T, et al. Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version. Clin Exp Nephrol. 2021;25:99-109.
PubMed
15) Yamaguchi Y, Kanetsuna Y, Honda K, et al. Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum Pathol. 2012;43:536-49.
PubMed
16) Arai H, Ogata S, Ozeki T, et al. Long-term changes in renal function after treatment initiation and the importance of early diagnosis in maintaining renal function among IgG4-related tubulointerstitial nephritis patients in Japan. Arthritis Res Ther. 2020;22:261.
PubMed
17) Saeki T, Kawano M, Mizushima I, et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int. 2013;84:826-33.
PubMed
18) Kawahara H, Mizushima I, Tsuge S, et al. Clues to mortality trends and their related factors in IgG4-related disease:a Japanese single-center retrospective study. Mod Rheumatol. 2022.
 
19) Saeki T, Kawano M, Mizushima I, et al. Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction. Clin Exp Nephrol. 2016;20:87-93.
PubMed
20) Sumimoto K, Uchida K, Ikeura T, et al. Nationwide epidemiological survey of immunoglobulin G4-related disease with malignancy in Japan. J Gastroenterol Hepatol. 2022;37:1022-33.
PubMed
P.196 掲載の参考文献
1) 厚生労働化学研究費補助金 難治性疾患政策研究事業 アミロイドーシスに関する調査研究班. 腎アミロイドーシスガイドライン2020.
 
2) Sayed RH, Hawkins PN, Lachmann HJ. Emerging treatments for amyloidosis. Kidney Int. 2015;87:516-26.
PubMed
3) Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis:origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8:1515-23.
PubMed
4) Nishi S, Muso E, Shimizu A, et al. A clinical evaluation of renal amyloidosis in the Japan renal biopsy registy:a cross-sectional study. Clin Exp Nephrol. 2017;21:624-32.
 
5) Dember LM. Amyloidosis-Associated Kidney Disease. J Am Soc Nephrol. 2006;17:3458-71.
PubMed
6) 日本血液学会. 造血器腫瘍診療ガイドライン 2018年版補訂版.
 
7) Rysava R. AL amyloidosis:advances in diagnostics and treatment. 2019;34:1460-6.
PubMed
8) Hutchison CA, Harding S, Hewins P, et al. Quantitative assesment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1684-990.
 
9) Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005;51:878-81.
PubMed
10) Mollee P, Tate J, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amylodosis. Clin Chem Lab. 2013;51:2303-10.
 
11) Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361-71.
PubMed
12) Okuda Y, Takasugi K. Successful use of a humanized antiinterleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54:2997-3000.
 
13) Yamada Y, Ueno T, Irifuku T, et al. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease:a case report. Clin Nephrol. 2018;90:232-6.
 
14) Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis a therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthiritides:a follow up report of tolerability and efficacy. Arthiritis Rheum. 2003;48:2019-24.
 
15) Locatelli F, Marcelli D, Conte F, et al. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int. 1999;55:286-93.
PubMed
16) Gejyo F, Kawaguchi Y, Hara S, et al. Arresting dialysis-related amyloidosis:a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microgloblin absorption column. Artif Organs. 2004;28:371-80.
 
P.202 掲載の参考文献
1) 日本骨髄腫学会, 編. 多発性骨髄腫の診療指針. 第5版. 東京:文光堂;2020. p.22-8.
 
2) Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55:1517-22.
PubMed
3) National Comprehensive Cancer Network(R). NCCN Guidelines Version 2. 2023, Multiple Myeloma.
 
4) Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance:when MGUS is no longer undetermined or insignificant. Blood. 2012;120:4292-95.
PubMed
5) Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance:a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15:45-59.
 
6) Klomjit N, Leung N, Fervenza F, et al. Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy. J Am Soc Nephrol. 2020;31:2400-11.
PubMed
7) Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis:safety run-in results of ANDROMEDA. Blood. 2020;136:71-80.
PubMed
P.212 掲載の参考文献
1) 難病情報センター 非典型溶血性尿毒症症候群(指定難病109). https://www.nanbyou.or.jp/entry/3847
 
2) Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP:an integrated approach. Hematology Am Soc Hematol Educ Program. 2018;2018:530-8.
PubMed
3) Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241-3.
 
4) Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335-46.
PubMed
5) Volker LA, Brinkkoetter PT, Knobl PN, et al. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab. J Thromb Haemost. 2020;18:3061-6.
PubMed
6) Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.
 
7) Yoshida Y, Miyata T, Matsumoto M, et al. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One. 2015;10:e0124655.
 
8) Fakhouri F, Fremeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond:clinical clues from complement genetics. Nature Reviews Nephrology. 2021;17:543-53.
PubMed
P.218 掲載の参考文献
1) Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813-21.
PubMed
2) Yoshida Y, Kashiwabara K, Hirakawa Y, et al. Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diabetes Res Care. 2020;8:e000902.
PubMed
3) Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18:1353-61.
PubMed
4) Ito H, Antoku S, Izutsu T, et al. The prognosis of subjects showing a reduced estimated glomerular filtration rate without albuminuria in Japanese patients with type 2 diabetes:a cohort study for diabetic kidney disease. Clin Exp Nephrol. 2020;24:1033-43.
PubMed
5) Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes:a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431-7.
PubMed
6) Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3):an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951-64.
PubMed
7) Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
PubMed
8) Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
PubMed
9) Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219-29.
PubMed
10) Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22.
PubMed
11) Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44.
PubMed
12) Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.
PubMed
13) Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57.
PubMed
14) Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57.
PubMed
15) Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306.
PubMed
16) Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587-97.
PubMed
17) de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease:a consensus report by the American Diabetes Association (ADA) and Kidney Disease:Improving Global Outcomes (KDIGO). Kidney Int. 2022;102:974-89.
PubMed
P.225 掲載の参考文献
1) 花房規男, 阿部雅紀, 常喜信彦, 他. わが国の慢性透析療法の現況(2020年12月31日現在). 透析会誌. 2022;54:611-57.
 
2) 厚生労働省. 平成28年国民健康・栄養調査報告(平成29年12月).
 
3) 三浦克之. 厚生労働行政推進調査事業費補助金. 循環器疾患・糖尿病等生活習慣病対策総合研究事業「新旧(1980-2020年)のライフスタイルからみた国民代表集団大規模コホート研究:NIPPON DATA80/90/2010/2020(H30-循環器等-指定-002)」平成30年総括・分担研究報告書, 2019.
 
4) Alpers CE, Fogo AB. Kidney and its collecting system. In:Kumar V, Abbas AK, Aster JC, et al;editors. Robbins Basic Pathology. Philadelphia:Elsevier;2013, p.539-40.
 
5) Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010;152:561-7.
PubMed
6) Ljungqvist A, Lagergren C. Normal intrarenal arterial pattern in adult and aging human kidney. A microangiographical and histological study. J Anat. 1962;96:285-300.
 
7) Tracy RE, Ishii T. What is 'nephrosclerosis'? lessons from the US, Japan, and Mexico. Nephrol Dial Transplant. 2000;15:1357-66.
PubMed
8) Lipkowitz MS, Freedman BI, Langefeld CD, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013;83:114-20.
PubMed
9) Bohle A, Ratschek M. The compensated and the decompensated form of benign nephrosclerosis. Pathol Res Pract. 1982;174:357-67.
PubMed
10) Abe M, Okada K, Maruyama N, et al. Comparison of clinical trajectories before initiation of renal replacement therapy between diabetic nephropathy and nephrosclerosis on the KDIGO guidelines heat map. J Diabetes Res. 2016;2016:5374746.
PubMed
11) 日本腎臓学会. エビデンスに基づくCKD診療ガイドライン2018. 東京:東京医学社;2018.
 
12) 日本高血圧学会. 高血圧治療ガイドライン2019. 東京:ライフサイエンス出版;2019
 

6章 遺伝性疾患 : 家族歴からルーツをたどる

P.234 掲載の参考文献
1) Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant, last update:September 29, 2022. GeneReviews(R) [internet].
 
2) Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019;380:142-51.
PubMed
3) 土谷 健, 眞壁志帆, 片岡浩史, 他. 多発性嚢胞腎の診断・治療の進歩. 人間ドック. 2017;32:444-55.
Medical*Online
4) Sekine A, Hidaka S, Moriyama T, et al. Cystic kidney disease that require a differential diagnosis from autosomal dominant polycystic kidney disease (ADPKD). J Clin Med. 2022;11:6528.
PubMed
5) Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393:919-35.
PubMed
6) Takada D, Sekine A, Yabuuchi J, et al. Renal histology and MRI in a 25-year-old Japanese man with nephronophthisis 4. Clin Nephrol. 2018;89:223-8.
 
7) 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班, 編. エビデンスに基づく多発性嚢胞腎(PKD)診療ガイドライン2020. 東京医学社;2020.
 
8) Iliuta IA, Kalatharan V, Wang K, et al. Polycystic kidney disease without an apparent family history. J Am Soc Nephrol. 2017;28:2768-76.
PubMed
9) Sekine A, Fujimaru T, Hoshino J, et al. Genotype-clinical correlations in polycystic kidney disease with no apparent family history. Am J Nephrol. 2019;49:233-40.
PubMed
10) Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Eng J Med. 2012;367:2407-18.
 
11) Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930-42.
PubMed
12) Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease:a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160-72.
PubMed
13) Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29:2458-70.
PubMed
14) Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predics the mutated gene in ADPKD. J Am Soc Nephrol. 2009;20:1833-8.
 
15) Cornec-Le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24:1006-13.
PubMed
16) Sekine A, Hoshino J, Fujimaru T, et al. Genetics May predict effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Am J Nephrol. 2020;51:745-51.
PubMed
17) Miyamoto R, Sekine A, Fujimaru T, et al. Echocardiographic findings and genotypes in autosomal dominant polycystic kidney disease. Kidney Dis. 2021;8:246-52.
PubMed
18) 望月俊雄. 多発性嚢胞腎における遺伝学的解析の臨床応用. 腎と透析. 2022;3:371-5.
Medical*Online
19) Lefevre S, Audrezet MP, Halimi JM, et al. Diagnosis and risk factors for intracranial aneurysms in autosomal polycystic kidney disease:a cross-sectional study from the Genkyst cohort. Nephrol Dial Transplant. 2022;37:2223-33.
PubMed
P.241 掲載の参考文献
1) Nozu K, Nakanishi K, Abe Y, et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol. 2019;23:158-68.
PubMed
2) Kashtan CE, Ding J, Garosi G, et al. Alport syndrome:a unified classification of genetic disorders of collagen IV α345:a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018;93:1045-51.
 
3) 日本小児腎臓病学会, 編. アルポート症候群診療ガイドライン2017. 診断と治療社;2017. p.1-85.
 
4) Yamamura T, Horinouchi T, Nagano C, et al. Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int. 2020;98:1605-14.
PubMed
5) Yamamura T, Nozu K, Fu XJ, et al. Natural history and genotype-phenotype correlation in female X-linked Alport syndrome. Kidney Int Rep. 2017;2:850-5.
PubMed
6) Oka M, Nozu K, Kaito H, et al. Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol. 2014;29:1535-44.
PubMed
7) Kamiyoshi N, Nozu K, Fu XJ, et al. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome. Clin J Am Soc Nephrol. 2016;11:1441-9.
PubMed
8) 高橋雄一, 鈴木俊明, 小林武弘, 他. α5鎖が正常に染色され菲薄基底膜症候群が疑われたが, 遺伝子解析で診断に至ったX連鎖性アルポート症候群の男性例(会議録). 日児腎誌. 2015;28:124.
 
9) Nakanishi K, Yoshikawa N, Iijima K, et al. Immunohistochemical study of alpha 1-5 chains of type IV collagen in hereditary nephritis. Kidney Int. 1994;46:1413-21.
PubMed
10) Hashimura Y, Nozu K, Kaito H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain. Kidney Int. 2014;85:1208-13.
 
11) Aoto Y, Horinouchi T, Yamamura T, et al. Last nucleotide substitutions of COL4A5 exons cause aberrant splicing. Kidney Int Rep. 2021;7:108-16.
PubMed
12) Krol RP, Nozu K, Nakanishi K, et al. Somatic mosaicism for a mutation of the COL4A5 gene is a cause of mild phenotype male Alport syndrome. Nephrol Dial Transplant. 2008;23:2525-30.
PubMed
P.247 掲載の参考文献
1) Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A Deficiency:Fabry disease, The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York:McGraw-Hill;2001. p.3733-74.
 
2) Sawada T, Kido J, Yoshida S, et al. Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep. 2020;22:100562.
PubMed
3) Kobayashi M, Ohashi T, Iizuka S, et al. Frequency of de novo mutations in Japanese patients with Fabry disease. Mol Genet Metab Rep. 2014;1:283-7.
PubMed
4) Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease:baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184-92.
PubMed
5) Mehta A, Ricci R, Widmer U, et al. Fabry disease defined:baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236-42.
PubMed
6) 日本先天代謝異常学会, 編. ファブリー病診療ガイドライン2020. 東京:診断と治療社;2021.
 
7) Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol. 2002;13:139-43.
 
8) Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease:progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102-11.
PubMed
9) Ortiz A, Germain DP, Robert J, et al. Fabry disease revisited:management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416-27.
 
10) Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease:conclusions from a "Kidney Disease:Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91:284-93.
PubMed
11) Shimohata H, Ogawa Y, Maruyama H, et al. A renal variant of Fabry disease diagnosed by the presence of urinary mulberry cells. Intern Med. 2016;55:3475-8.
PubMed
12)Yonishi H, Namba-Hamano T, Hamano T, et al. Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy. Nephrol Dial Transplant. 2022;37:53-62.
 
13) Maruyama H, Miyata K, Mikame M, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21:44-52.
PubMed
14) Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52:353-8.
PubMed
P.256 掲載の参考文献
1) Yao T, Udwan K, John R, et al. Integration of genetic testing and pathology for the diagnosis of adults with FSGS. Clin J Am Soc Nephrol. 2019;14:213-23.
PubMed
2) Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019;380:142-51.
PubMed
3) Goodship TH, Cook HT, Fakhouri F, et al;Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy:conclusions from a "Kidney Disease:Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91:539-51.
PubMed
4) Fujisawa M, Kato H, Yoshida Y, et al. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol. 2018;22:1088-99.
PubMed
5) Savige J, Renieri A, Ars E, et al. Digenic Alport syndrome. Clin J Am Soc Nephrol. 2022;17:1697-706.
PubMed

7章 間質疾患 : 腎機能障害の本質

P.262 掲載の参考文献
1) Goicoehea M, Rivera F, Lopez-Gomez JM, et al. Increased prevalence of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2013;28:112-5.
 
2) Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011:a case series. Am J Kidney Dis. 2014;64:558-66.
PubMed
3) Gupta S, Cortazar FB, Riella LV, et al. Immune checkpoint inhibitor nephrotoxicity:update 2020. Kidney360. 2020;1:130-40.
PubMed
4) Seethpathy H, Zhao S, Chute DF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14:1692-700.
 
5) Shah S, Carter-Monroe N, Atta MG, et al. Granulomatous interstitial nephritis. Clin Kidney J. 2015;8:516-23.
PubMed
6) Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis:report and analysis of 15 cases. Nephrology (Carlton). 2006;11:381-5.
PubMed
7) Praga M, Gonzalez E. Acute interstitial nephritis. Kidney Int. 2010;77:956-61.
PubMed
8) Gonzalez E, Gutierrez E, Galeano C, et al. Early steroid treatment improves renal function recovery in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73:940-6.
 
9) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. 2012;Suppl 2:1-138.
 
10) Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis:clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19:2778-83.
 
11) Neelakantappa K, Gallo GR, Lowenstein J. Ranitidine-associated interstitial nephritis and Fanconi syndrome. Am J Kidney Dis. 1993;22:333-6.
PubMed
12) Shibasaki T, Ishimoto F, Sakai O, et al. Clinical characterization of drug-induced allergic nephritis. Am J Nephrol. 1991;11:174-80.
PubMed
13) Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24:64-71.
PubMed
14) Ulinski T, Sellier-Leclerc AL, Tudorache E, et al. Acute tubulointerstitial nephritis. Pediatric Nephrology. 2012;27:1051-7.
PubMed
15) Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22:1343-52.
PubMed
16) Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin J Am Soc Nephrol. 2017;12:2046-9.
PubMed
17) Preddie DC, Markowits GS, Radhakrishnan J, et al. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol. 2006;1:718-22.
 
18) Ix JH, Shlipak MG. The promise of tubule biomarkers in kidney disease:a review. Am J Kidney Dis. 2021;78:719-27.
PubMed
P.269 掲載の参考文献
1) Palmer BF, Kelepouris E, Deborah JC. Renal tubular acidosis and management strategies:narrative review. Adv Ther. 2021;38:949-68.
 
2) Emmett M, Kelepouris E. Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance. https://www.uptodate.com/contents/overview-and-pathophysiology-of-renal-tubular-acidosis-and-effect-on-potassium-balance. last updated:Sep 14,2021.
 
3) Trepiccione F, Prosperi F, de la Motte LR, et al. New findings on the pathogenesis of distal renal tubular acidosis. Kidney Dis (Basel). 2017;3:98-105.
PubMed
4) Kashoor I, Batle D. Proximal renal tubular acidosis with and without Fanconi syndrome. Kidney Dis. 2018;38:267-81.
 
5) Haque SK, Ariceta G, Batle D. Proximal renal tubular acidosis:a not so rare disorder of multiple etiologies. Nephrol Dial Transplant. 2012;27:4273-87.
 
6) Donnelly S, Kamel KS, Vasuvattakul S, et al. Might distal renal tubular acidosis be a proximal tubular cell disorder? Am J Kidney Dis. 1992;19:272-81.
 
7) Unwin RJ, Capasso G. The renal tubular acidosis. J R Soc Med. 2001;94:221-5.
PubMed
8) Palmer BF, Clegg DJ. Hyperchloremic normal gap metabolic acidosis. Minerva Endocrinol. 2019;44:363-77.
PubMed
9) Wesson DE, Mather V, Tangri N, et al. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease:a multicentre, randomized, blinded, placebo-controlled, 40-week extension. Lancet. 2019;394:396-406.
 
P.276 掲載の参考文献
1) Amraoui F, Bos S, Vogt L, et al. Long-term renal outcome in patients with malignant hypertension:a retrospective cohort study. BMC Nephrol. 2012;13:71.
PubMed
2) Januszewicz A, Guzik T, Prejbisz A, et al. Malignant hypertension:new aspects of an old clinical entity. Pol Arch Med Wewn. 2016;126:86-93.
PubMed
3) Shantsila A, Lip GYH. Malignant hypertension revisited-does this still exist? Am J Hypertens. 2017;30:543-9.
PubMed
4) Bidani AK, Griffin KA, Plott W, et al. Renal ablation acutely transforms 'benign' hypertension to 'malignant' nephrosclerosis in hypertensive rats. Hypertension. 1994;24:309-16.
PubMed
5) van den Born BJ, Honnebier UP, Koopmans RP, et al. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005;45:246-51.
PubMed
6) Demeulenaere M, Devreese K, Vanbelleghem H, et al. Thrombomodulin and endothelial dysfunction:a disease-modifier shared between malignant hypertension and atypical hemolytic uremic syndrome. Nephron. 2018;140:63-73.
PubMed
7) 日本高血圧学会. 高血圧治療ガイドライン2019. 東京:ライフサイエンス出版;2019.
 
8) Kaplan NM. Hypertensive emergencies. Kaplan's Clinical Hyptertension, 2015. 2015:263-74.
 
9) Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension:The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953-2041.
 

8章 特殊な場合の腎障害 : 一流のコンサルタントへの近道

P.284 掲載の参考文献
1) Christiansen CF, Johansen MB, Langeberg WJ, et al. Incidence of acute kidney injury in cancer patients:a Danish population-based cohort study. Eur J Intern Med. 2011;22:399-406.
PubMed
2) Lahoti A, Nates JL, Wakefield CD, et al. Costs and outcomes of acute kidney injury in critically ill patients with cancer. J Support Oncol. 2011;9:149-55.
 
3) 宮本佳尚, 南学正臣, 土井研人. がん診療と急性腎障害. 日腎会誌. 2017;59:615-8.
 
4) Sato K, Watanabe S, Ohtsubo A, et al. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer. 2016;16:222-7.
PubMed
5) Latcha S, Jaimes EA, Patil S, et al. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11:1173-9.
PubMed
6) 日本腎臓学会, 日本癌治療学会, 日本臨床腫瘍学会, 日本腎臓病薬物療法学会, 編. がん薬物療法時の腎障害診療ガイドライン2022. 東京:ライフサイエンス出版;2022.
 
7) 和田健彦. OnconephrologyにおけるAKI. 日内会誌. 2021;110:935-41.
 
8) 和田健彦. 免疫チェックポイント阻害薬と腎障害. 日腎会誌. 2022;64:410-7.
 
P.291 掲載の参考文献
1) Bihorac A, Yavas S, Subbiah S, et al. Long-term risk of acute kidney injury during hospitalization after major surgery. Ann Surg. 2009;249:851-8.
PubMed
2) An Y, Shen K, Ye Y. Risk factors for and the prevention of acute kidney injury after abdominal surgery. Surg Today. 2018;48:573-83.
PubMed
3) Romagnoli S, Ricci Z. Postoperative acute kidney injury. Minerva Anestesiol. 2015;81:684-96.
PubMed
4) Yeo KK, Li Z, Yuen JY, et al. Severity of chronic kidney disease as a risk factor for operative mortality in nonemergent patients in California coronary artery bypass graft surgery outcomes reporting program. Am J Cardiol. 2008;101:1269-74.
 
5) Kidney Disease Improving Global Outcomes (KDIGO):Practice Guideline for Acute Kidney Injury. Kidney Int. 2012;Suppl 2:1-138.
 
6) 日本透析医学会, 編. 2011年版慢性血液透析用バスキュラーアクセスの作成および修復に関するガイドライン. 透析会誌. 2011;44:855-937.
 
7) Hazel Z, Wald R, Bergman JM, et al. Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. Kidney Int. 2013;83:901-8.
 
8) Castaidi PA, Rosenberg MC, Stewart JH. The bleeding disorder of uremia:a qualitative platelet defect. Lancet. 1966;2:66-9.
 
9) Kanda H, Hirosaki Y, Iida T, et al. Perioperative management of patients with end-stage renal disease. Cardiothoratic Vascular Anesth. 2017;31:2251-67.
 
10) Moran SM, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int. 1985;27:928-37.
 
P.298 掲載の参考文献
1) 日本腎臓学会, 日本医学放射線学会, 日本循環器学会, 他. 腎障害患者におけるヨード造影剤使用に関するガイドライン2018. 日本腎臓学会誌. 2019;61:933-1081.
 
2) Mehdi A, Taliercio JJ, Nakhoul G. Contrast media in patients with kidney disease:An update. Cleve Clin J Med. 2020;87:683-94.
PubMed
3) 岡田浩一.【急性腎不全(ARF)から急性腎障害(AKI)へ】造影剤腎症の管理. 日本医師会雑誌. 2022;151:33-6.
 
4) Chertow GM, Normand SL, McNeil BJ. "Renalism":inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol. 2004;15:2462-8.
PubMed
5) Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease:consensus statements from the American College of Radiology and the National Kidney Foundation. Kidney Med. 2020;2:85-93.
PubMed
6) Miyamoto Y, Iwagami M, Aso S, et al. Association between intravenous contrast media exposure and non-recovery from dialysis-requiring septic acute kidney injury:a nationwide observational study. Intensive Care Med. 2019;45:1570-9.
PubMed
7) Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-61.
PubMed
8) Ozkok A. Cholesterol-embolization syndrome:current perspectives. Vasc Health Risk Manag. 2019;15:209-20.
PubMed
9) Fukumoto Y, Tsutsui H, Tsuchihashi M, et al;Cholesterol Embolism Study Investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization:a prospective study. J Am Coll Cardiol. 2003;42:211-6.
 
10) Ishiyama K, Sato T. Efficacy of LDL apheresis for the treatment of cholesterol crystal embolism:a prospective, controlled study. Ther Apher Dial. 2022;26:456-64.
PubMed
11) Oloko A, Talreja H, Davis A, et al. Does iodinated contrast affect residual renal function in dialysis patients? A systematic review and meta-analysis. Nephron. 2020;144:176-84.
PubMed
P.304 掲載の参考文献
1) 日本妊娠高血圧学会, 編.妊娠高血圧症候群の診療指針2021. 東京:メディカルビュー社;2021.
 
2) Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-83.
PubMed
3) Chaemsaithong P, Pooh RK, Zheng M, et al. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. Am J Obstet Gynecol. 2019;221:650.e1-650.e16.
 
4) 日本腎臓学会学術委員会, 編. 腎疾患の妊娠 診療ガイドライン2017. 東京:診断と治療社;2017.
 
5) Rao S, Jim B. Acute kidney injury in pregnancy:the Changing Landscape for the 21st Century. Kidney Int Rep. 2018;3:247-57.
PubMed
6) 日本腎臓学会腎生検ガイドブック改訂委員会, 編. 腎生検ガイドブック2020. 東京:東京医学社;2020.
 
7) Mateus J, Newman RB, Zhang C, et al. Fetal growth patterns in pregnancy-associated hypertensive disorders:NICHD Fetal Growth Studies. Am J Obstet Gynecol. 2019;221:635. e1-635. e16.
 
8) Patterson AJ, Chen M, Xue Q, et al. Chronic prenatal hypoxia induces epigenetic programming of PKC {epsilon} gene repression in rat hearts. Circ Res. 2010;107:365-73.
 
9) Palma LMP, Sridharan M, Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep. 2021;6:11-23.
PubMed
10) Yoshida Y, Kato H, Ikeda Y, et al. Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb. 2019;26:99-110.
PubMed
11) Kumar D, King M, Jim B, et al. Recurrent case of pregnancy-induced atypical haemolytic uremic syndrome (P-aHUS). BMJ Case Rep. 2019;12:bcr-2018-226571.
 
12) Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21:859-67.
PubMed
13) Kozlovskaya NL, Korotchaeva YV, Shifman EM, et al. Atypical hemolytic-uremic syndrome as one of the causes of acute kidney injury in pregnant women. Ter Arkh. 2018;90:28-34.
PubMed
P.311 掲載の参考文献
1) Uemura O, Honda M, Matsuyama T, et al. Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children:a multicenter study. Clin Exp Nephrol. 2011;15:694-9.
PubMed
2) Uemura O, Ushijima K, Nagai T, et al. Reference serum creatinine levels determined by an enzymatic method in Japanese children:relationship to body length. Clin Exp Nephrol. 2009;13:585-8.
PubMed
3) Uemura O, Nagai T, Ishikura K, et al. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626-33.
PubMed
4) Uemura O, Ishikura K, Gotoh Y, et al. Creatinine-based estimated glomerular filtration rate for children younger than 2 years. Clin Exp Nephrol. 2018;22:483-4.
PubMed
5) Warady BA, Chadha V. Chronic kidney disease in children:the global perspective. Pediatr Nephrol. 2007;22:1999-2009.
PubMed
6) Hirano D, Ishikawa T, Inaba A, et al. Epidemiology and clinical features of childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis:a clinicopathological analysis. Pediatr Nephrol. 2019;34:1425-33.
PubMed
7) 日本小児内分泌学会(性分化・副腎疾患委員会, マススクリーニング委員会), 他. 21-水酸化酵素欠損症の診断・治療のガイドライン(2021年改訂版). 厚生労働省難治性疾患政策研究事業(副腎ホルモン産生異常に関する調査研究). https://www.jsms.gr.jp/download/CAH_Guideline_2021_revised_10-27.pdf
 
8) Punthakee Z, Legault L, Polychronakos C. Prednisolone in the treatment of adrenal insufficiency:A re-evaluation of relative potency. J Pediatr. 2003;143:402-5.
PubMed
9) Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia:The ability to achieve normal growth. Pediatrics. 2000;106:767-73.
PubMed
10) 日本小児腎臓病学会. 難治性疾患政策研究事業「小児腎領域の希少・難治性疾患群の診療・研究体制の確立」(厚生労働科学研究費補助金). 小児特発性ネフローゼ症候群診療ガイドライン2020. https://minds.jcqhc.or.jp/docs/gl_pdf/G0001231/4/Idiopathic_nephrotic_syndrome_in_children.pdf
 
11) 日本小児腎臓病学会. 小児IgA腎症診療ガイドライン2020. https://minds.jcqhc.or.jp/docs/gl_pdf/G0001187/4/iga_nephropathy_in_children.pdf
 
12) 学校検尿のすべて(令和2年度改訂). 日本学校保健会;2021.
 
P.318 掲載の参考文献
1) Usui J, Tawara-Iida T, Takada K, et al. Temporal changes in post-infectious glomerulonephritis in Japan (1976-2009). PLoS One. 2016;11:e0157356.
PubMed
2) Usui J, Kabayashi M, Ebihara I, et al. Methicillin-resistant Staphylococcus aureus-associated glomerulonephritis on the decline:Decreased incidence since the 1990s. Clin Exp Nephrol. 2011;15:184-6.
 
3) Koyama A, Kobayashi M, Yamaguchi N, et al. Glomerulonephritis associated with MRSA infection:a possible role of bacterial superantigen. Kidney Int. 1995;47:207-16.
PubMed
4) Nasr SH, Markowitz GS, Whelan JD, et al. IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol. 2003;34:1235-41.
PubMed
5) Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis. 2004;43:617-23.
PubMed
6) Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int. 2006;69:436-9.
PubMed
7) Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408-17.
PubMed
8) Perez de Jose A, Carbayo J, Pocurull A, et al. Direct-acting therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia:the RENALCRYOGLOBULINEMIC study. Clin Kidney J. 2021;14:586-92.
PubMed
9) Marras D, Bruggeman LA, Gao F, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med. 2002;8:522-6.
PubMed
10) De Silva TI, Post FA, Griffin MD, et al. HIV-1 infection and the kidney:an evolving challenge in HIV medicine. Mayo Clin Proc. 2007;82:1103-16.
PubMed
11) Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant. 2006;21:2809-13.
PubMed
P.325 掲載の参考文献
1) Zhou Y, Yang Q, Chi J, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019:a systematic review and meta-analysis. Int J Infect Dis. 2020;99:47-56.
PubMed
2) Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19:a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21:e13128.
PubMed
3) Matsunaga N, Hayakawa K, Terada M, et al. Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan:report of the COVID-19 registry Japan. Clin Infect Dis. 2020;73:e3677-e89.
 
4) Katagiri D, Asai Y, Ohmagari N, et al. Urinary L-type fatty acid-binding protein predicts oxygen demand of COVID-19 in initially mild cases. Crit Care Explor. 2023;5:e0873.
PubMed
5) Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS):an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020;22:95-7.
PubMed
6) Gu SX, Tyagi T, Jain K, et al. Thrombocytopathy and endotheliopathy:crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021;18:194-209.
PubMed
7) Ortega-Paz L, Capodanno D, Montalescot G, et al. Coronavirus disease 2019-associated thrombosis and coagulopathy:review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc. 2021;10:e019650.
PubMed
8) Chung EYM, Palmer SC, Natale P, et al. Incidence and outcomes of COVID-19 in people with CKD:a systematic review and meta-analysis. Am J Kidney Dis. 2021;78:804-15.
PubMed
9) 診療の手引き検討委員会. 新型コロナウイルス感染症診療の手引き 第10.0版. 2023.
 
10) Girardot T, Schneider A, Rimmele T. Blood purification techniques for sepsis and septic AKI. Semin Nephrol. 2019;39:505-14.
PubMed
11) Tang L, Yin Z, Hu Y, et al. Controlling cytokine storm is vital in COVID-19. Front Immunol. 2020;11:570993.
 
12) Katagiri D, Ishikane M, Asai Y, et al. Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. J Clin Apheresis. 2021;36:313-21.
PubMed
13) Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury:consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16:747-64.
PubMed
14) Katagiri D, Ishikane M, Ogawa T, et al. Continuous renal replacement therapy for a patient with severe COVID-19. Blood Purif. 2021;50:129-31.
PubMed
15) Huang W, Li B, Jiang N, et al. Impact of the COVID-19 pandemic on patients with chronic kidney disease:a narrative review. Medicine (Baltimore). 2022;101:e29362.
PubMed
16) Terakawa K, Katagiri D, Shimada K, et al. Safety of casirivimab/imdevimab administration during maintenance dialysis in SARS-CoV-2-positive patients in Japan. CEN Case Rep. 2022;11:328-32.
PubMed
17) Ashby DR, Caplin B, Corbett RW, et al. Severity of COVID-19 after vaccination among hemodialysis patients:an observational cohort study. Clin J Am Soc Nephrol. 2022;17:843-50.
PubMed
18) Aiswarya D, Arumugam V, Dineshkumar T, et al. Use of remdesivir in patients with COVID-19 on hemodialysis:a study of safety and tolerance. Kidney Int Rep. 2021;6:586-93.
PubMed
19) Kikuchi K, Nangaku M, Ryuzaki M, et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan:a nationwide cohort study. Ren Replace Ther. 2021;7:59.
PubMed
20) Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29:2347-57.
PubMed
21) Copur S, Berkkan M, Basile C, et al. Post-acute COVID-19 syndrome and kidney diseases:what do we know? J Nephrol. 2022;35:795-805.
 

9章 腎代替療法 : 80年前, 腎臓病は100 % 死亡した

P.332 掲載の参考文献
1) Lin CL, Huang CC, Chang CT, et al. Clinical improvement by increased frequency of online hemodialfiltration. Ren Fail. 2001;23:193-206.
PubMed
2) Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol. 2010;21:1798-807.
PubMed
3) 日本透析医学会. わが国の慢性透析療法の現況(2020年12月31日現在). 透析会誌. 2021;54:611-57.
 
4) 新田孝作, 政金生人, 花房規男, 他. わが国の慢性透析療法の現況(2017年12月31日現在). 透析会誌. 2018;51:699-766.
 
5) Burton JO, Jefferies HJ, Selby NM, et al. Hemodialysis-induced cardiac injury:determinants and associated outcomes. Clin J Am Soc Nephrol. 2009;4:914-20.
PubMed
6) Assimon MM, Wenger JB, Wang L, et al. Ultrafiltration rate and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2016;68:911-22.
PubMed
7) 2015年版 日本透析医学会 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌. 2016;49:89-158.
 
8) Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy:an angiographic examination. J Am Soc Nephrol. 2005;16:1141-8.
PubMed
9) Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91:31-8.
PubMed
10) Kalantar-Zadeh K, Hoffken B, Wunsch H, et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995;26:292-9.
PubMed
P.338 掲載の参考文献
1) Uchiyama K, Washida N, Yube N, et al. The impact of a remote monitoring system of healthcare resource consumption in patients on automated peritoneal dialysis (APD):a simulation study . Clin Nephrol. 2018;90:334-40.
PubMed
2) Sanabria M, Buitrago G, Lindholm B, et al. Remote patient monitoring program in automated peritoneal dialysis:impact on hospitalizations. Perit Dial Int. 2019;39:472-8.
PubMed
3) Corzo L, Wilkie M, Vesga JI, et al. Technique failure in remote patient monitoring program in patients undergoing automated peritoneal dialysis:a retrospective cohort study. Perit Dial Int. 2022;42:288-96.
PubMed
4) 日本腎臓学会, 他編. 腎代替療法選択ガイド2020. 東京:ライフサイエンス出版;2020. p.42.
 
5) Nakayama M, Miyazaki M, Honda K, et al. Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions:the NEXT-PD study. Perit Dial Int. 2014;34:766-74.
PubMed
6) Kawanishi K, Honda K, Tsukada M, et al. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Perit Dial Int. 2013;33:242-51.
PubMed
7) Cho Y, Johnson DW, Badve S, et al. Impact of icodextrin on clinical outcomes in peritoneal dialysis:a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2013;28:1899-907.
PubMed
8) Maruyama Y, Yokoyama K, Higuchi C, et al. Clinical feasibility of transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis:a prospective multicenter study in Japan. Ther Apher Dial. 2022;26:1226-34.
PubMed
P.348 掲載の参考文献
1) Kukita K, Ohira S, Amano I, et al. 2011 update Japanese Society for Dialysis Therapy Guidelines of Vascular Access Construction and Repair for Chronic Hemodialysis. Ther Apher Dial. 2015;19 Suppl 1:1-39.
 
2) 久木田 和, 大平整爾, 天野 泉, 他. 2011年版社団法人日本透析医学会 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌. 2011;44:855-937.
 
3) Ouchi H, Nishi H, Nakamura M, et al. Vascular Ehlers-Danlos syndrome diagnosed in a patient initiating hemodialysis. Kidney Int Rep. 2019;4:1646-8.
 
4) Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction:a cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17:1112-27.
PubMed
5) Campos B, Lee T, Roy-Chaudhury P. Arteriovenous fistula failure:is there a role for epigenetic regulation? Semin Nephrol. 2013;33:400-6.
 
6) Wasse H, Huang R, Naqvi N, et al. Inflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients. J Vasc Access. 2012;13:168-74.
PubMed
7) Roy-Chaudhury P, Wang Y, Krishnamoorthy M, et al. Cellular phenotypes in human stenotic lesions from haemodialysis vascular access. Nephrol Dial Transplant. 2009;24:2786-91.
PubMed
8) Roy-Chaudhury P, Arend L, Zhang J, et al. Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis. 2007;50:782-90.
PubMed
9) Stracke S, Konner K, Kostlin I, et al. Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int. 2002;61:1011-9.
PubMed
10) Simone S, Loverre A, Cariello M, et al. Arteriovenous fistula stenosis in hemodialysis patients is characterized by an increased adventitial fibrosis. J Nephrol. 2014;27:555-62.
PubMed
11) Brahmbhatt A, Remuzzi A, Franzoni M, et al. The molecular mechanisms of hemodialysis vascular access failure. Kidney Int. 2016;89:303-16.
PubMed
12) Li L, Terry CM, Shiu YT, et al. Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int. 2008;74:1247-61.
PubMed
13) Lookstein RA, Haruguchi H, Ouriel K, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med. 2020;383:733-42.
PubMed
14) Trerotola SO, Lawson J, Roy-Chaudhury P, et al;Investigators LACT. Drug coated balloon angioplasty in failing AV fistulas:a randomized controlled trial. Clin J Am Soc Nephrol. 2018;13:1215-24.
 
P.355 掲載の参考文献
1) 花房規男, 阿部雅紀, 常喜信彦, 他. わが国の慢性透析療法の現況(2020年12月31日現在). 透析会誌.2021;54:611-57.
 
2) ファクトブック2021 Fact Book 2021 on Organ Transplantation in Japan, 日本移植学会.
 
3) 生体腎移植のドナーガイドライン. 日本移植学会・日本臨床腎移植学会 生体腎移植ドナーガイドライン策定合同委員会, 日本腎臓学会・腎移植推進委員会. https://www.jscrt.jp/wp-content/themes/jscrt/pdf/guideline/guideline3.pdf
 
4) International Registry in Organ Donation and Transplantation (IRODaT) database 2022. https://www.irodat.org/?p=database
 
5) 内閣府ホームページ. http://survey.gov-online.go.jp/h25/h25-zouki/index.html
 
6) https://www.jotnw.or.jp/files/page/facilities/list02/offer_facilities.pdf
 
7) 日本移植学会登録委員会. わが国における臓器移植のための臓器摘出の現状と実績(2021). 187-93.
Medical*Online
8) 日本腎臓学会, 日本透析医学会, 日本腹膜透析医学会, 日本臨床腎移植学会, 日本小児腎臓病学会, 編. 腎代替療法選択ガイド. 東京:ライフサイエンス出版;2020.
 
9) 日本臓器移植ネットワーク. https://www.jotnw.or.jp/files/news1/2020/rec-kidney.pdf
 

10章 社会精神的問題 : 最後は心の問題です

P.363 掲載の参考文献
1) Davison SN, Levin A, Moss AH, et al;Kidney Disease Improving Global Outcomes. Executivesummary of the Kidney Disease Improving Global Outcomescontroversies conference on supportive care in chronickidney disease:Developing a roadmap to improving quality care. Kidney Int. 2015;88:447-59. Available at:https://kdigo.org/.
 
2) Foote C, Kotwal S, Gallagher M, et al. Survival outcomes of supportive care versus dialysis therapies for elderly patients with end-stage kidney disease:a systematic review and meta-analysis. Nephrology (Carlton). 2016;21:241-53.
PubMed
3) Verberne WR, Geers AB, Jellema WT, et al. Comparative survival among older adults with advanced kidney disease managed conservatively versus with dialysis. Clin J Am Soc Nephrol. 2016;11:633-40.
PubMed
4) 日本透析医学会透析調査委員会. わが国の慢性透析療法の現況(2021年12月31日現在). 透析会誌. 2022;55:665-723.
 
5) Yazawa M, Kido R, Ohira S, et al. Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients:A Cohort Study of the Large National Dialysis Registry. PLoS One. 2016;11:e0156951.
PubMed
6) Brennan F, Stewart C, Burgess H, et al. Time to improve informed consent for dialysis:an international perspective. Clin J Am Soc Nephrol. 2017;12:1001-9.
PubMed
7) Beacham TL, Chlidress JF. The definition and elements of informed consent. In Principles of Biomedical Ethics. 8th ed. Oxford Univ Press;2019. p.119-23.
 
8) Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and chemo prevention. a suggested approach from the U.S. Preventive Services Task Force. Am J Prevent Med. 2004;26:56-66.
 
9) World Health Organization. http://www.who.int/cancer/palliative/definition/en/ Accessed 12 April 2016.
 
10) O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis:a systematic review. J Palliat Med. 2012;15:228-35.
PubMed
11) Thomas BA, Rodriguez RA, Boyko EJ, et al. Geographic variation in black- white differences in end-of-life care for patients with ESRD. Clin J Am Soc Nephrol. 2013;8:1171-8.
PubMed
12) 会田薫子. 臨床倫理の基礎. In:清水哲郎, 会田薫子, 田代志門, 編.臨床倫理の考え方と実践-医療・ケアチームのための事例検討法. 東京:東京大学出版会;2022.
 
13) 樋口範雄. 続・医療と法を考える-終末期医療ガイドライン. 東京:有斐閣;2008.
 
14) 米村滋人. 医事法講義. 東京:日本評論社;2016.
 
15) 前田和彦. 医事法講義. 東京:信山社;2016.
 
16) 手嶋 豊. 医師患者関係と法規範. 東京:信山社;2020.
 
17) 甲斐克則, 編. 終末期医療と医事法. 東京:信山社;2013.
 
18) 厚生労働省. 人生の最終段階における医療・ケアの決定プロセスに関するガイドライン. 2018. https://www.mhlw.go.jp/file/04-Houdouhappyou-10802000-Iseikyoku-Shidouka/0000197701.pdf
 
19) 日本透析医学会. 透析の開始と継続に関する意思決定プロセスについての提言. 透析会誌. 2020;53:173-217.
 
20) 「日本医療研究開発機構(AMED)長寿科学研究開発事業高齢腎不全患者に対する腎代替療法の開始/見合わせの意思決定プロセスと最適な緩和医療・ケアの構築」研究班, 編. 高齢腎不全患者のための保存的腎臓療法-conservative kidney management(CKM)の考え方と実践-. 東京:東京医学社;2022.
 

書評

最近チェックした商品履歴

Loading...